Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
出版年份 2019 全文链接
标题
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
作者
关键词
-
出版物
Journal of Crohns & Colitis
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2019-11-27
DOI
10.1093/ecco-jcc/jjz195
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Microbial network disturbances in relapsing refractory Crohn’s disease
- (2019) Bahtiyar Yilmaz et al. NATURE MEDICINE
- Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease
- (2019) Bram Verstockt et al. EBioMedicine
- Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients with Inflammatory Bowel Diseases
- (2019) Konrad Aden et al. GASTROENTEROLOGY
- Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
- (2019) Nicholas A Kennedy et al. Lancet Gastroenterology & Hepatology
- Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
- (2018) A. Barré et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials
- (2018) Siddharth Singh et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study
- (2018) Marco Vincenzo Lenti et al. DIGESTIVE AND LIVER DISEASE
- Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease
- (2018) Elisa K. Boden et al. DIGESTIVE DISEASES AND SCIENCES
- Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-label Trial of Patients With Ulcerative Colitis
- (2018) Shannon E. Telesco et al. GASTROENTEROLOGY
- Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD
- (2018) Renaud Gaujoux et al. GUT
- Genetic Markers Predict Primary Nonresponse and Durable Response to Anti–Tumor Necrosis Factor Therapy in Ulcerative Colitis
- (2018) Kristin E Burke et al. INFLAMMATORY BOWEL DISEASES
- How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease
- (2018) Samuele Naviglio et al. Expert Review of Gastroenterology & Hepatology
- Inflammatory bowel disease: towards a personalized medicine
- (2018) Mathurin Flamant et al. Therapeutic Advances in Gastroenterology
- Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn’s Disease
- (2018) Belén Beltrán et al. DIGESTIVE DISEASES
- Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry
- (2018) María Chaparro et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy
- (2018) Toer W. Stevens et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients
- (2018) Igor Vladimirovich Obraztsov et al. INFLAMMATORY BOWEL DISEASES
- Clinical usefulness of proteomics in inflammatory bowel disease: A comprehensive review
- (2018) Javier P Gisbert et al. Journal of Crohns & Colitis
- Ustekinumab en el tratamiento de la enfermedad de Crohn
- (2017) Javier P. Gisbert et al. Gastroenterologia y Hepatologia
- Molecular imaging of mucosal α4β7 integrin expression with the fluorescent anti-adhesion antibody vedolizumab in Crohn’s disease
- (2017) Timo Rath et al. GASTROINTESTINAL ENDOSCOPY
- Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study
- (2017) Yoram Bouhnik et al. GUT
- Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
- (2017) Carlos Taxonera et al. INFLAMMATORY BOWEL DISEASES
- Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience
- (2017) Uri Kopylov et al. INFLAMMATORY BOWEL DISEASES
- Can We Predict the Efficacy of Anti-TNF-α Agents?
- (2017) Loris Lopetuso et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy
- (2017) D. G. Ribaldone et al. IRISH JOURNAL OF MEDICAL SCIENCE
- Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study
- (2017) Lauren Beswick et al. Journal of Crohns & Colitis
- Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease
- (2017) Nathaniel R West et al. NATURE MEDICINE
- Clinical Significance of Bmi1 Expression in Inflammatory Bowel Disease
- (2017) Mitsunari Yamada et al. ONCOLOGY
- Pharmacogenetic biomarkers of response in Crohn’s disease
- (2017) T M Linares-Pineda et al. PHARMACOGENOMICS JOURNAL
- Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy
- (2017) S Bank et al. PHARMACOGENOMICS JOURNAL
- Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn’s disease
- (2017) Thomas Billiet et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Ustekinumab use in Crohn’s disease: a Canadian tertiary care centre experience
- (2017) Astrid-Jane Greenup et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease
- (2017) Uri Netz et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease
- (2017) Azade Amini Kadijani et al. Clinical and Translational Gastroenterology
- The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease
- (2016) N. Narula et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease
- (2016) N. To et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients
- (2016) L. Angelison et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
- (2016) D. C. Baumgart et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases
- (2016) S. Bek et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
- (2016) A. Stallmach et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn’s Disease
- (2016) Grant E Barber et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium
- (2016) Parambir S Dulai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents
- (2016) Pauline Wils et al. Clinical Gastroenterology and Hepatology
- Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
- (2016) Aurelien Amiot et al. Clinical Gastroenterology and Hepatology
- Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis
- (2016) Gaik W. Tew et al. GASTROENTEROLOGY
- Patients with Refractory Crohnʼs Disease Successfully Treated with Ustekinumab
- (2016) Kimberly A. Harris et al. INFLAMMATORY BOWEL DISEASES
- Role of Vitamin D in Infliximab-induced Remission in Adult Patients with Crohnʼs Disease
- (2016) Krista M. Reich et al. INFLAMMATORY BOWEL DISEASES
- Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy
- (2016) Valeria Caneparo et al. INFLAMMATORY BOWEL DISEASES
- Ustekinumab for the Treatment of Refractory Crohnʼs Disease
- (2016) Sam Khorrami et al. INFLAMMATORY BOWEL DISEASES
- Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease
- (2016) Namita Singh et al. INFLAMMATORY BOWEL DISEASES
- Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition
- (2016) Maria K. Magnusson et al. Journal of Crohns & Colitis
- Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohn’s Disease
- (2016) Peter Brown et al. Journal of Crohns & Colitis
- Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis
- (2016) Iris Detrez et al. Journal of Crohns & Colitis
- 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
- (2016) Fernando Gomollón et al. Journal of Crohns & Colitis
- Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients
- (2016) Marisa Iborra et al. JOURNAL OF GASTROENTEROLOGY
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Prospective Pharmacogenomic Study of Crohn's Disease Patients during Routine Therapy with Anti-TNF-α Drug Adalimumab: Contribution ofATG5,NFKB1,andCRPGenes to Pharmacodynamic Variability
- (2016) Matjaž Deželak et al. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
- Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-α antibodies in ulcerative colitis
- (2016) Yukihiro Morita et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
- (2016) Marta Maia Bosca-Watts et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy
- (2016) Angela C Baird et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study
- (2016) Chang Hwan Choi et al. YONSEI MEDICAL JOURNAL
- Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
- (2016) Uri Kopylov et al. Therapeutic Advances in Gastroenterology
- Does Smoking Reduce Infliximab’s Effectiveness against Crohn’s Disease?
- (2016) Neeraj Narula et al. CANADIAN JOURNAL OF GASTROENTEROLOGY
- Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study
- (2015) W. J. Sandborn et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONICpost hocanalysis
- (2015) J.-F. Colombel et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Cultured blood T-cell responses predict anti-TNF therapy response in patients with ulcerative colitis
- (2015) M. K. Magnusson et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed
- (2015) J. P. Gisbert et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management
- (2015) N. S. Ding et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
- (2015) L Peyrin-Biroulet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis
- (2015) Maria Theresa Arias et al. Clinical Gastroenterology and Hepatology
- Vedolizumab en el tratamiento de la enfermedad de Crohn
- (2015) Javier P. Gisbert et al. Gastroenterologia y Hepatologia
- The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
- (2015) Andres J Yarur et al. GUT
- Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients
- (2015) Edward Shelton et al. INFLAMMATORY BOWEL DISEASES
- A Matrix-based Model Predicts Primary Response to Infliximab in Crohn’s Disease
- (2015) Thomas Billiet et al. Journal of Crohns & Colitis
- Response to Infliximab in Crohn’s Disease: Genetic Analysis Supporting Expression Profile
- (2015) Luz María Medrano et al. MEDIATORS OF INFLAMMATION
- Genetic polymorphism inATG16L1gene influences the response to adalimumab in Crohn's disease patients
- (2015) Silvo Koder et al. PHARMACOGENOMICS
- Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy
- (2015) Rahil Dahlén et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- pANCA Positivity Predicts Lower Clinical Response to Infliximab Therapy among Patients with IBD
- (2015) Douglas L. Nguyen et al. SOUTHERN MEDICAL JOURNAL
- Genetic Polymorphisms ofIL-17FandTRAF3IP2Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn’s Disease
- (2015) Shigetoshi Urabe et al. Biomed Research International
- Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease
- (2014) R. W. Stidham et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Early Intervention with Adalimumab May Contribute to Favorable Clinical Efficacy in Patients with Crohn's Disease
- (2014) Jun Miyoshi et al. DIGESTION
- Physiological Intermolecular Modification Spectroscopy for the Prediction of Response to Anti-Tumor Necrosis Factor Therapy in Patients with Inflammatory Bowel Diseases
- (2014) Pierre Eftekhari et al. DIGESTIVE DISEASES
- Molecular Patterns in Human Ulcerative Colitis and Correlation with Response to Infliximab
- (2014) Brendan Halloran et al. INFLAMMATORY BOWEL DISEASES
- Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease
- (2014) Iris Dotan et al. INFLAMMATORY BOWEL DISEASES
- Incidence and Predictors of Clinical Response, Re-induction Dose, and Maintenance Dose Escalation with Certolizumab Pegol in Crohnʼs Disease
- (2014) Adam C. Stein et al. INFLAMMATORY BOWEL DISEASES
- Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature
- (2014) Yael Haberman et al. JOURNAL OF CLINICAL INVESTIGATION
- Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience
- (2014) U. Kopylov et al. Journal of Crohns & Colitis
- Smoking and Early Infliximab Response in Crohn's Disease: a Meta-analysis
- (2014) S. Inamdar et al. Journal of Crohns & Colitis
- Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients
- (2014) Charlotte P. Peters et al. Journal of Crohns & Colitis
- Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
- (2014) Séverine Vermeire et al. LANCET
- In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease
- (2014) Raja Atreya et al. NATURE MEDICINE
- Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease
- (2014) S Bank et al. PHARMACOGENOMICS JOURNAL
- Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn’s disease
- (2014) Diamantis Thomas WORLD JOURNAL OF GASTROENTEROLOGY
- Optimizing anti-TNF treatments in inflammatory bowel disease
- (2013) Shomron Ben-Horin et al. AUTOIMMUNITY REVIEWS
- Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment
- (2013) Gordon W. Moran et al. Clinical Gastroenterology and Hepatology
- Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
- (2013) Jean–Frédéric Colombel et al. Clinical Gastroenterology and Hepatology
- Severe Disease Activity and Cytomegalovirus Colitis Are Predictive of a Nonresponse to Infliximab in Patients with Ulcerative Colitis
- (2013) Sang Hyoung Park et al. DIGESTIVE DISEASES AND SCIENCES
- Adalimumab for Crohn’s disease after infliximab treatment failure
- (2013) Wei Da et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Role of TNFRSF1B polymorphisms in the response of Crohn’s disease patients to infliximab
- (2013) L.M. Medrano et al. HUMAN IMMUNOLOGY
- FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity
- (2013) Rintaro Moroi et al. IMMUNOGENETICS
- Genetic polymorphisms of tumour necrosis factor alpha (TNF-α) promoter gene and response to TNF-α inhibitors in Spanish patients with inflammatory bowel disease
- (2013) R. López-Hernández et al. International Journal of Immunogenetics
- Serum protein profile of Crohn's disease treated with infliximab
- (2013) Maria Gazouli et al. Journal of Crohns & Colitis
- High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment
- (2013) Fernando Magro et al. Journal of Crohns & Colitis
- Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study
- (2013) Kang-Moon Lee et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Towards personalized care in IBD
- (2013) Mark E. Gerich et al. Nature Reviews Gastroenterology & Hepatology
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis
- (2013) Qiang Tong et al. PHARMACOGENOMICS
- The challenges of stratifying patients for trials in inflammatory bowel disease
- (2013) Paolo Biancheri et al. TRENDS IN IMMUNOLOGY
- C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I
- (2012) W. Reinisch et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study
- (2012) F. Zorzi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease
- (2012) C. Steenholdt et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn’s disease and ulcerative colitis
- (2012) Diana Lacruz-Guzmán et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease
- (2012) Amit Assa et al. Journal of Crohns & Colitis
- Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome
- (2012) Orlando García-Bosch et al. Journal of Crohns & Colitis
- Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis
- (2012) Renathe Rismo et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Crohn’s disease genotypes of patients in remissionvsrelapses after infliximab discontinuation
- (2012) Cathy Lu WORLD JOURNAL OF GASTROENTEROLOGY
- Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease
- (2011) L. S. Kiss et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
- (2011) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease
- (2011) Matthias Jürgens et al. Clinical Gastroenterology and Hepatology
- Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
- (2011) Adedigbo A. Fasanmade et al. CLINICAL THERAPEUTICS
- Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience
- (2011) José Ignacio Fortea-Ormaechea et al. Gastroenterologia y Hepatologia
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
- (2011) W. Reinisch et al. GUT
- Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
- (2011) A.A. Fasanmade et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience
- (2011) Michael B. Sprakes et al. Journal of Crohns & Colitis
- Genetic and genomic predictors of anti-TNF response
- (2011) Rita Prajapati et al. PHARMACOGENOMICS
- NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report
- (2011) M. Barreiro-de Acosta et al. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS
- Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn’s disease
- (2010) H. MATSUKURA et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy and Hospitalization
- (2010) Abderrahim Oussalah et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?
- (2010) Geert R D'Haens et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Disease Activity, ANCA and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis
- (2010) Matthias Jürgens et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
- (2010) Stefan Schreiber et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn’s Disease
- (2010) Cristina Nichita et al. DIGESTION
- Peripheral regulatory T cells and serum transforming growth factor-β: Relationship with clinical response to infliximab in Crohnʼs disease
- (2010) Antonio Di Sabatino et al. INFLAMMATORY BOWEL DISEASES
- Predictive value of epithelial gene expression profiles for response to infliximab in Crohnʼs disease‡
- (2010) Ingrid Arijs et al. INFLAMMATORY BOWEL DISEASES
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab
- (2009) C. MA et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis
- (2009) Trine Olsen et al. CYTOKINE
- Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis
- (2009) William J. Sandborn et al. GASTROENTEROLOGY
- Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
- (2009) I. Arijs et al. GUT
- Genome wide association (GWA) predictors of anti-TNFα therapeutic responsiveness in pediatric inflammatory bowel disease
- (2009) Marla C. Dubinsky et al. INFLAMMATORY BOWEL DISEASES
- Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease
- (2009) Corey A. Siegel et al. Therapeutic Advances in Gastroenterology
- Proteomics for prediction and characterization of response to infliximab in Crohn's disease: A pilot study
- (2008) Marie-Alice Meuwis et al. CLINICAL BIOCHEMISTRY
- Predicting Factors of Fistula Healing and Clinical Remission After Infliximab-Based Combined Therapy for Perianal Fistulizing Crohn’s Disease
- (2008) David Tougeron et al. DIGESTIVE DISEASES AND SCIENCES
- Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response
- (2008) Yago González-Lama et al. Gastroenterologia y Hepatologia
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
- Long-term outcome after infliximab for refractory ulcerative colitis
- (2008) Marc Ferrante et al. Journal of Crohns & Colitis
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
- (2008) Geert D'Haens et al. LANCET
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started